Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain

XBiotech (NASDAQ: XBIT) announced the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with...

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease

XBiotech (NASDAQ:XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate...